SecBot SecBot
8-K ·Filed Nov 9, 2026

IMNM

Immunome Inc.
BEARISH
Impact 5/10
Horizonmonths Processed7d 10h ago SEC0001193125-26-453556
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The wider-than-expected loss and accelerating cash burn are the headline negatives, but the varegacestat PDUFA date and EMA validation are key regulatory catalysts. Watch for ASH data on IM-1021 on Dec 14 and the varegacestat approval decision in April 2027.

DirectionBearish
Confidencehigh
Horizonmonths

Drugs in focus

IMNM drug pipeline →

varegacestat

▲ Bullish Named in this 8-K
Impact
Phase
Filed/PDUFA
Time to market
FDA PDUFA target action date is April 28, 2027. EMA review is also underway following MAA validation in October 2026. If approved, varegacestat could launch in the US in the second half of 2027.
Next catalyst
PDUFA date · Apr 28, 2027 162d

What to watchThe single most important catalyst is the FDA PDUFA decision on April 28, 2027. Approval would make varegacestat the second FDA-approved therapy for desmoid tumors and unlock a meaningful commercial opportunity, while a Complete Response Letter would severely pressure the stock given the company's pre-revenue status and reliance on this asset. Watch for EMA review progress and Q3 earnings on November 16 for pipeline updates and cash runway details.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$18.65
T+0 close · Nov 9, 2026 · via day close
Latest settled
+2.25%
T+1 · $19.07 · next T+5 in 4h
Vs SPY
+0.93%
α at T+1
Latest observation
−1.66%
T+4 · FF3 residual α
  1. T+0 · Nov 10 $18.65entry
  2. T+1 · 6d ago +2.25%α +0.93% · $19.07
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cash and securities totaled $461.6M, down from $582.7M at Q1 end, with cash runway into 2028. Key pipeline milestones include an FDA PDUFA date of April 28, 2027 for varegacestat, EMA MAA validation, and IND clearance for IM-1340.

Key Financial Metrics

Revenue
$0.00
est $133.0K · -100.0%

Key Facts

  • Net loss of $85.8M for Q3 2026, vs $57.5M in Q3 2025
  • Cash, cash equivalents and marketable securities totaled $461.6M as of Sep 30, 2026
  • R&D expenses rose to $69.5M from $49.2M year-over-year
  • Varegacestat PDUFA target action date set for April 28, 2027
  • EMA validated MAA for varegacestat in October 2026
  • IND clearance received for IM-1340 in September 2026
  • Initial IM-1021 results showed 53% ORR in B-NHL; updated data expected at ASH Dec 14

Financial Impact

Net loss widened to $85.8M from $57.5M; EPS miss of -26.7% vs consensus

net lossepscash burnr&d expenses

Risk Factors

  • Cash burn rate increased significantly (R&D +41% YoY), reducing cash runway despite guidance into 2028
  • No revenue or collaboration income reported; pre-commercial stage with no near-term product sales
  • Regulatory risk for varegacestat ahead of PDUFA date
  • Early-stage pipeline (IM-1021, IM-1617, IM-3050, IM-1340) carries clinical and commercial risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-453556
Document: imnm-20261109.htm0001193125-26-453556
Document: 0001193125-26-453556-index-headers.html0001193125-26-453556
Document: 0001193125-26-453556-index.html0001193125-26-453556
Document: 0001193125-26-453556.txt0001193125-26-453556
8-K Data (Synthetic)0001193125-26-453556

Track record

20 reports on IMNM

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.53% at T+60 after the May 28, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
  2. Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
  3. Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
  4. Nov 9, 20267d ago 8-K Bearish 5/10 Viewing Entry $18.65 Now $17.61 +5.58% settles Feb 8
  5. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
  6. Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
  7. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
  8. Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Entry $20.89 Now $17.61 +15.70% settles Dec 28
  9. Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Entry $25.07 Now $17.61 −29.76% settles Dec 15
  10. Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026